First patient treated with TOOsonix HIFU in skin cancer study.

The dermatology departments at Bispebjerg and Roskilde University Hospitals in Denmark initiate pioneering treatment of Basal Cell Carcinoma, the world’s most common cancer, with the convenient, minimal-pain and easy-to-operate modality for skin oncology facilitated by the TOOsonix System ONE-M.

Basal Cell Carcinoma (BCC) is sun-induced and is expected to increase in incidence along with the increase of the elderly population. Adding safe, effective, and cost-efficient treatments will therefore be important for both patients and healthcare providers around the world.

The clinical study will include 40 patients diagnosed with superficial BCC. The focused ultrasound treatment will be administered as a single dosing of approximately 1-2 minutes of active focused ultrasound. The treatment does not require any local anesthetics and no special after-care. Study participants are monitored with regular follow-up visits over 12 months after treatment. A report with evaluation of cure rate and safety profile 3 months after treatment is planned.

See the full Press Release here.